Health Care
As pandemic boom fades, Moderna’s market momentum reverses
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market.
Section
Pfizer
Pfizer
Pfizer is looking for its next blockbusters after Covid. Could one of them be treating cancer?
Photo: Wikimedia Commons Covid made Pfizer a household name and sent its revenues and profits soaring.
COVID-19
Pfizer Sales Down As Demand for Covid Products Fall
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines.
Company Insights
Pfizer seeks partnerships to broaden and diversify its portfolio
Image by Mike Ramírez Mx from Pixabay Pharmaceutical giant Pfizer has teamed up with a biology biotech company Ginkgo Bioworks to research and develop RNA medicines, following a series of acquisitions and partnerships to grow and diversify its portfolio With the deal of up to $331 million the two companies plan to work on up to three
Company Insights
Moderna, Pfizer Stocks Down Even Amid Rising Covid-19 Cases and Updated Boosters Launch
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.
AstraZeneca
Moderna says vaccine produces antibodies in seniors, pushes ahead in Warp Speed race
Moderna Inc.